The potential mechanism of Choulingdan mixture in improving acute lung injury based on HPLC–Q‐TOF–MS, network pharmacology and in vivo experiments
Biomedical Chromatography · 2023
DOI: 10.1002/bmc.5709 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2023. Verfasst von Lili Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China. Hauptthemen laut MEDLINE: Acute Lung Injury, Drugs, Chinese Herbal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 74 Literaturangaben. Gefördert von: Basic Research Program of Yunnan Provincial Department of Science and Technology (Key Projects), Kunming Hospital of Traditional Chinese Medicine, Yunnan Province, China.
Abstract (Originalsprache)
Choulingdan mixture (CLDM) is an empirical clinical prescription for the adjuvant treatment of acute lung injury (ALI). CLDM has been used for almost 30 years in the clinic. However, its mechanism for improving ALI still needs to be investigated. In this study, high‐performance liquid chromatography–quadrupole/time‐of‐flight mass spectrometry (HPLC–Q‐TOF–MS/MS) was applied to characterize the overall chemical composition of CLDM. A total of 93 ingredients were characterized, including 25 flavonoids, 20 organic acids, 11 saponins, nine terpenoids, seven tannins and 21 other compounds. Then network pharmacology was applied to predict the potential bioactive components, target genes and signaling pathways of CLDM in improving ALI. Additionally, molecular docking was performed to demonstrate the interaction between the active ingredients and the disease targets. Finally, animal experiments further confirmed that CLDM significantly inhibits pulmonary inflammation, pulmonary edema and oxidative stress in lipopolysaccharide‐induced ALI mice by inhibiting the PI3K–AKT signaling pathway. This study enhanced the amount and accuracy of compounds of CLDM and provided new insights into CLDM preventing and treating ALI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
- Department of Pharmacy, Kunming Municipal Hospital of Traditional Chinese Medicine, Kunming, China.
ORCID-Profile: Hui Xie
Förderung
- Basic Research Program of Yunnan Provincial Department of Science and Technology (Key Projects)
- Kunming Hospital of Traditional Chinese Medicine, Yunnan Province, China
Zitieren
APA
Wang, L., Li, Z., Lu, T., Su, L., Mao, C., Zhang, Y., Zhang, X., Jiang, X., Xie, H., & Yu, X. (2023). The potential mechanism of Choulingdan mixture in improving acute lung injury based on HPLC–Q‐TOF–MS, network pharmacology and in vivo experiments. Biomedical Chromatography. https://doi.org/10.1002/bmc.5709
Vancouver
Wang L, Li Z, Lu T, Su L, Mao C, Zhang Y, et al. The potential mechanism of Choulingdan mixture in improving acute lung injury based on HPLC–Q‐TOF–MS, network pharmacology and in vivo experiments. Biomedical Chromatography. 2023. doi:10.1002/bmc.5709
BibTeX
@article{Wang2023,
author = {Wang, Lili and Li, Zhengyan and Lu, Tulin and Su, Lianlin and Mao, Chunqin and Zhang, Yiting and Zhang, Xinrui and Jiang, Xiaofeng and Xie, Hui and Yu, Xiaoling},
title = {The potential mechanism of Choulingdan mixture in improving acute lung injury based on HPLC–Q‐TOF–MS, network pharmacology and in vivo experiments},
journal = {Biomedical Chromatography},
year = {2023},
doi = {10.1002/bmc.5709}
}
EUVIMED